INDICATIONS

PAVBLU™ (aflibercept-ayyh) is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

PAVBLU™ (aflibercept-ayyh) is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration ...Read more

Indications Prescribing Information AmgenSupportPlus.com AmgenBiosimilars.com

Understanding your treatment with PAVBLU™

UNDERSTANDING YOUR EYE CONDITION

PAVBLU™ is a Food and Drug Administration (FDA)-approved prescription medication used to treat the following eye conditions:1,*
  • Wet age-related macular degeneration, known as “wet AMD”
  • Diabetic macular edema (DME)
  • Diabetic retinopathy (DR)
  • Macular edema following retinal vein occlusion (RVO)

*PAVBLU™ is not indicated for Retinopathy of Prematurity, for which Regeneron has marketing exclusivity.1,2

Wet AMD

Wet AMD occurs with age when abnormal blood vessels grow in the back of the eye. These may leak and damage part of your retina3,4

Diabetic macular edema (DME) and diabetic retinopathy (DR)

DME and DR occur when diabetes causes blood vessels in the back of the eye to become damaged or blocked, which can cause fluid to leak and damage the retina5-7

Macular edema following retinal vein occlusion, or RVO

RVO occurs when fluid leaks into the back of the eye due to a blocked blood vessel and can damage the retina8

All of these conditions cause leaking fluid in the back of the eye and can damage the retina.1,9

VEGF = vascular endothelial growth factor.

Diagram illustrating retina damage caused by VEGF protein production
Symptoms of these conditions can include:9-11
Symptoms of Wet AMD, DME, DR, and RVO
  • « Straight lines begin to look wavy or crooked
  • « Blurry area near the center of your vision
  • « Blank spots, dark spots, or little squiggles in vision (floaters)
  • « Trouble seeing in low light
  • « Sudden blurring or loss of vision (over days to weeks)
Is there a treatment for these conditions?
PAVBLU™ is an anti-VEGF treatment that can help with these conditions. VEGF (vascular endothelial growth factor) is a protein made by our cells to form blood vessels. When it is produced at high levels, it can cause the overgrowth of blood vessels and cause them to leak fluid. PAVBLU™ helps to block that protein.1,9
Diagram illustrating how PAVBLU™ (aflibercept) can block VEGF
Diagram illustrating PAVBLU™ (aflibercept-ayyh) mechanism of action
About Your Diagnosis Patient About-Your-Diagnosis-Patient-mob
Amgen is a worldwide leader in innovator biologics and biosimilars, with experience and expertise you can trust

PAVBLU™ is a biosimilar of the biologic medicine called EYLEA®

Both PAVBLU™ and EYLEA® work with your body to help stop or slow the progression of certain retinal conditions. PAVBLU™ is proven to provide a similar treatment benefit to EYLEA®.1-3
Symptoms of wet AMD

In wet AMD, high levels of VEGF in the eye cause blood vessels to grow and leak fluid into the macula, the part of the eye that controls sharp, detailed central vision.1,4

PAVBLU™ binds to VEGF, which helps prevent it from causing 
new blood vessels to form and leak fluid in the eye.1
PAVBLU™ can help stop or slow the progression of symptoms of your retinal disease, helping you maintain your current level of vision.1,3

AMD = age-related macular degeneration; VEGF = vascular endothelial growth factor.

Switching from EYLEA® TO PAVBLU™

The dosing and administration of PAVBLU™ is identical and provides a similar experience if you are switching from EYLEA®—no need to restart your dosing schedule1,2

PAVBLU™ is given by your doctor in the same way and frequency as EYLEA® for a highly similar TREATMENT experience1,2

PAVBLU™ (aflibercept) is administered using the same injection method as EYLEA®SAME INJECTION METHOD
PAVBLU™ (aflibercept) dosing frequency is the same as EYLEA®SAME DOSING FREQUENCY
How PAVBLU™ WORKS Patient How-PAVBLU-WORKS-mob
At Amgen, we’re committed to every patient, every time

AMGEN—A Worldwide Leader in INNOVATOR Biologics and Biosimilars

Amgen has been providing biologic medicines to patients for more than 40 years. It’s known throughout the world as a leader in research, development, and manufacturing of complex medicines.

40+

Years

AMGEN has been a leader in Biologics1

~10M

Patients are treated

with an Amgen medication each year2

Amgen biosimilars are developed, manufactured, and distributed with the same high standards as our innovator biologics
Amgen has a global network of scientistsGLOBAL NETWORK OF SCIENTISTS
Amgen has the same key manufacturing facilities in North America and EuropeGLOBAL MANUFACTURING FACILITIES
Amgen has a state-of-the-art distribution networkSTATE OF THE ART DISTRIBUTION NETWORK
Why AMGEN Biosimilars Patient Why-AMGEN-Biosimilars-mob
At Amgen, we maintain the highest standards for all our medicines

Support throughout your treatment journey

Amgen® SupportPlus Sample Co-pay CardAMGEN® SUPPORTPLUS CO-PAY PROGRAM

AMGEN® SUPPORTPLUS CO-PAY PROGRAM

If you have private or commercial insurance that you get from your employer or buy directly from an insurance company, you may be eligible for the Amgen® SupportPlus Co-Pay Program.*

  • Eligible patients may pay as little as $0 out-of-pocket for each dose and receive up to $1,000 per calendar year for in-office administration out-of-pocket costs*
  • No income eligibility requirement
View terms and conditions at AmgenSupportPlus.com/copay

*Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay for full Terms and Conditions. Massachusetts and Rhode Island residents not eligible for in-office administration support.

Government Insurance

If you have government insurance, like Medicare, Amgen® SupportPlus can provide information about resources that may be able to lower your out-of-pocket costs.†

†Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit's criteria. Amgen has no control over these programs and provides information as a courtesy only.

Amgen® SupportPlus logo
Amgen® SupportPlus is here to help from the moment you're prescribed PAVBLU™. Visit AmgenSupportPlus.com or call Amgen® SupportPlus at (866) 264-2778 Monday - Friday 9:00 am - 8:00 pm ET
My PAVBLU™ Guide
My PAVBLU™ Guide

My PAVBLU™ Guide was co-created with patients to help you get answers to the most important questions about starting a biologic treatment, establishing a treatment routine, what results you may expect, and understanding the available support services.

DOWNLOAD GUIDE
PAVBLU™ Patient Brochure
PAVBLU™ Patient Brochure - Downloadable

Learn more about your retinal condition and how PAVBLU™ may be able to help. Get answers to important questions about starting a biologic treatment, establishing a treatment routine and understanding the available support services.

DOWNLOAD Brochure

Important Safety Information

  • PAVBLU™ (aflibercept-ayyh) Injection is a prescription medicine administered by injection into the eye. You should not use PAVBLU™ if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in PAVBLU™.
  • Injections into the eye with PAVBLU™ can result in an infection in the eye, retinal detachment (separation of retina from back of the eye) and, more rarely, serious inflammation of blood vessels in the retina that may include blockage. Call your doctor right away if you experience eye pain or redness, light sensitivity, or a change in vision after an injection.
  • In some patients, injections with PAVBLU™ may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
  • There is a potential but rare risk of serious and sometimes fatal side effects, related to blood clots, leading to heart attack or stroke in patients receiving PAVBLU™.
  • The most common side effects reported in adult patients receiving aflibercept were increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, vitreous floaters, moving spots in the field of vision, and increased pressure in the eye.
  • You may experience temporary visual changes after a PAVBLU™ injection and associated eye exams; do not drive or use machinery until your vision recovers sufficiently.
  • For additional safety information, please talk to your doctor and see the full Prescribing Information for PAVBLU™.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS

PAVBLU™ (aflibercept-ayyh) is a prescription medicine approved for the treatment of Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please click here for full Prescribing Information for PAVBLU™.

Important Safety Information

  • PAVBLU™ (aflibercept-ayyh) Injection is a prescription medicine administered by injection into the eye. You should not use PAVBLU™ if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in PAVBLU™.